Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Brain Neoplasms 21Carcinoma, Non-Small-Cell Lung 16Pancreatic Neoplasms 11Neoplasm Metastasis 11Prostatic Neoplasms 9Melanoma 9Lung Neoplasms 8Glioblastoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Squamous Cell Carcinoma of Head and Neck 6Glioma 6Carcinoma, Renal Cell 6Neoplasms 5Colorectal Neoplasms 5Head and Neck Neoplasms 4Uveal Melanoma 3Oligodendroglioma 3Liver Neoplasms 3Gliosarcoma 3Astrocytoma 3Adenocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2

Interventions

aflutinib 3osimertinib 2Radiotherapy 2tipifarnib 1apatinib 1Radiosurgery 1Immune Checkpoint Inhibitors 1Gefitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NSCLC × Radiosurgery × Clear all
NCT05615142 2026-05-11

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Sichuan University

Phase 1 Active not recruiting
9 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡